BiotechTube

Gemcitabine + Oxaliplatin + Bevacizumab

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer

Conditions

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Trial Timeline

Sep 1, 2006 → Oct 1, 2011

NCT ID
NCT00418093

About Gemcitabine + Oxaliplatin + Bevacizumab

Gemcitabine + Oxaliplatin + Bevacizumab is a phase 2 stage product being developed by Eli Lilly for Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00418093. Target conditions include Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

What happened to similar drugs?

11 of 20 similar drugs in Ovarian Cancer were approved

Approved (11) Terminated (4) Active (7)
✅OlaparibAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved
✅Ganirelix acetateMerckApproved
✅Triptorelin 0.2 mgMerckApproved
✅Pegylated Liposomal Doxorubicin hydrochlorideMerckApproved
✅fosaprepitant + aprepitantMerckApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00418093Phase 2Terminated
NCT00142467Phase 2Completed

Competing Products

20 competing products in Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
azenosertibZentalis PharmaceuticalsPhase 2
32
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
22
pemetrexed + topotecanEli LillyPhase 1
29
arzoxifene hydrochlorideEli LillyPhase 2
35
LY4337713Eli LillyPhase 1
36
PrexasertibEli LillyPhase 2
35
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
32
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
42
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
47
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
35
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
32
Enzalutamide 40 MGAstellas PharmaPhase 2
35
ASP0739Astellas PharmaPhase 1/2
24
IMAB027Astellas PharmaPhase 1
29
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
35